Results 31 to 40 of about 1,070,166 (331)

Safety of Janus Kinase Inhibitors in Patients with Inflammatory Bowel Diseases or Other Immune-mediated Diseases: a Systematic Review and Meta-Analysis.

Gastroenterology, 2020
BACKGROUND & AIMS Inhibitors of Janus kinases (JAKs) are being developed for treatment of inflammatory bowel diseases and other immune-mediated diseases. Tofacitinib is effective in treatment of ulcerative colitis, but there are safety concerns.
P. Olivera, J. Lasa, S. Bonovas, S. Danese, L. Peyrin-Biroulet   +4 more
semanticscholar   +1 more source

Features of Crohn's Disease Depending on the Age of Disease Onset

Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2023
Aim: to evaluate the characteristics of Crohn's disea depending on the age of the disease onset in patients observed in a specialized City Center for Inflammatory Bowel Diseases Diagnosis and Treatment.Materials and methods. We observed 180 patients with
E. G. Ganich, O. B. Shchukina
doaj   +1 more source

Environmental Risk Factors for Inflammatory Bowel Diseases: an Umbrella Review of Meta-analyses.

Gastroenterology, 2019
BACKGROUND & AIMS Multiple environmental factors have been associated with development of inflammatory bowel diseases (IBD). We performed an umbrella review of meta-analyses to summarize available epidemiologic evidence and assess its credibility ...
D. Piovani, S. Danese, L. Peyrin-Biroulet, G. Nikolopoulos, T. Lytras, S. Bonovas   +5 more
semanticscholar   +1 more source

Dextran sodium sulfate colitis murine model: An indispensable tool for advancing our understanding of inflammatory bowel diseases pathogenesis

World Journal of Gastroenterology, 2017
Inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis, are complex diseases that result from the chronic dysregulated immune response in the gastrointestinal tract.
D. Eichele, K. Kharbanda
semanticscholar   +1 more source

Substance P Mediates Proinflammatory Cytokine Release From Mesenteric Adipocytes in Inflammatory Bowel Disease PatientsSummary

Cellular and Molecular Gastroenterology and Hepatology, 2015
Background & Aims: Substance P (SP) neurokinin-1 receptors (NK-1Rs) are expressed in mesenteric preadipocytes, and SP binding activates proinflammatory signaling in these cells. We evaluated the expression levels of SP (Tac-1), NK-1R (Tacr-1), and NK-2R (
Aristea Sideri, Kyriaki Bakirtzi, David Q. Shih, Hon Wai Koon, Phillip Fleshner, Razvan Arsenescu, Violeta Arsenescu, Jerrold R. Turner, Iordanes Karagiannides, Charalabos Pothoulakis   +9 more
doaj   +1 more source

Nutritional Aspects in Inflammatory Bowel Diseases

Nutrients, 2020
Crohn’s disease (CD) and ulcerative colitis (UC) are chronic, relapsing, inflammatory disorders of the digestive tract that characteristically develop in adolescence and early adulthood.
P. Balestrieri, M. Ribolsi, M. Guarino, S. Emerenziani, A. Altomare, M. Cicala   +5 more
semanticscholar   +1 more source

Identification of a Novel Substance P–Neurokinin-1 Receptor MicroRNA-221-5p Inflammatory Network in Human Colonic Epithelial CellsSummary

Cellular and Molecular Gastroenterology and Hepatology, 2015
Background & Aims: Substance P (SP), a neuropeptide member of the tachykinin family, plays a critical role in colitis. MicroRNAs (miRNAs) are small noncoding RNAs that negatively regulate gene expression.
Kai Fang, Aristea Sideri, Ivy Ka Man Law, Kyriaki Bakirtzi, Christos Polytarchou, Dimitrios Iliopoulos, Charalabos Pothoulakis   +6 more
doaj   +1 more source

Mesenteric excision surgery or conservative limited resection in Crohn’s disease: study protocol for an international, multicenter, randomized controlled trial

Trials, 2020
Background The structures of the mesentery including adipose tissue, nerves, and lymphatics play an important role in the pathogenesis and disease progression of Crohn’s disease (CD).
Yi Li, Helen Mohan, Nan Lan, Xiaojian Wu, Wei Zhou, Jianfeng Gong, Bo Shen, Luca Stocchi, J. Calvin Coffey, Weiming Zhu   +9 more
doaj   +1 more source

2019 novel coronavirus disease (COVID‐19) in patients with inflammatory bowel diseases

Alimentary Pharmacology and Therapeutics, 2020
Data on patients with inflammatory bowel diseases (IBD) who have had 2019 novel coronavirus (SARS‐CoV‐2) disease (COVID‐19) are needed.
C. Taxonera, Iñigo Sagastagoitia, C. Alba, N. Manas, D. Olivares, E. Rey   +5 more
semanticscholar   +1 more source

The microbiome in inflammatory bowel diseases: from pathogenesis to therapy

Protein & Cell, 2020
Inflammatory bowel disease (IBD) has become a global disease with accelerating incidence worldwide in the 21st century while its accurate etiology remains unclear.
Sheng Liu, Wenjing Zhao, P. Lan, Xiangyu Mou   +3 more
semanticscholar   +1 more source